Systems Thinking in Pharmaceutical Access: Future-Proofing Value Strategy

By Rene Pretorius

March 26, 2025

As global healthcare systems grow more budget-focused, complex, and dynamic, pharma companies must evolve their value and access strategies accordingly. Systems-thinking-in-pharmaceutical-access offers a powerful framework—helping commercial and access teams build adaptable, resilient strategies that extend beyond traditional HTA methods such as cost-effectiveness models.

By embracing a systems lens, manufacturers can anticipate challenges, engage stakeholders more effectively, and align with long-term health system goals.

Why Systems Thinking in Pharmaceutical Access Is a Strategic Imperative

Anticipating Complexity Across the Product Lifecycle

Systems thinking helps market access teams map the evolving interdependencies between clinical, economic, and policy dimensions.  The importance of these interdependencies are evident in regulatory shifts in the EU through the JCA. Systems thinking facilitates early identification of access barriers, emerging policy risks, and system-level opportunities for value optimization.

Enabling Proactive, Evidence-Based Access Planning

In an era of HTA-driven reimbursement and value-based care, systems thinking in pharmaceutical access supports integrated planning—from pipeline to post-launch. It informs robust evidence strategies, value proposition development, and stakeholder alignment.

Addressing Structural and Systemic Access Barriers

Applying systems thinking allows companies to diagnose and overcome structural bottlenecks. Typical challenges are fragmented reimbursement pathways, misaligned incentives, or inequities in care delivery. This is especially valuable for shaping local access strategies in complex healthcare environments.

Aligning with Broader Health System Objectives

Payers are increasingly focused on sustainability, health equity, and system-wide outcomes. A systems-based approach positions pharmaceutical innovation as a contributor to broader societal value, strengthening the case for reimbursement and funding.

Strategic Advantages for Global Value and Market Access Teams

  • Enhanced Stakeholder Engagement:
    Systems thinking provides a shared framework for dialogue across stakeholders—enabling better alignment with payer expectations, provider realities, and patient needs.

  • Smarter Evidence Generation:
    Identifying feedback loops and systemic risks helps prioritize data collection and real-world evidence generation that support both regulatory and HTA goals.

  • Greater Agility in Evolving Policy Contexts:
    Systems thinking in pharmaceutical access enhances the adaptability of value strategies in the face of changing HTA criteria, budget constraints, or policy reform.

  • Improved Risk Management:
    Proactively anticipating how decisions on price, access, or value impact the wider health ecosystem supports better mitigation planning and execution.

Conclusion

To stay competitive in a rapidly changing global landscape, pharma companies must embed systems thinking in access strategies. This empowers market access and HEOR teams to anticipate change, align with stakeholders, and deliver sustainable value across health systems.

Reference url

Recent Posts

access to medicines
         

Quantifying EU Medicine Access Challenges

🔍 Are we creating a healthcare system that truly works for everyone?

Recent findings from EFPIA shed light on alarming inequities in access to medicines across Europe, showing that only 46% of approved drugs are available to patients this year. With significant delays affecting smaller markets and critical cancer treatments, this article explores the systemic barriers at play and innovative solutions proposed to ensure fair access.

Dive into the full article to uncover how we can collectively shape a more equitable healthcare landscape.

#SyenzaNews #healthcare #MarketAccess

UK Medicine Payment Rates
      

Revitalizing Innovation: The Impact of UK Medicine Payment Rates

💡 Are the UK’s medicine payment rates stifling innovation in life sciences?

Recent analysis reveals that the staggering 23.5% payment rate for pharmaceuticals is not just limiting NHS spending but also curtailing R&D investments, delaying new drug launches, and threatening workforce stability. If we can lower these rates to below 10%, we could unleash significant growth and restore the UK’s competitive edge in the global life sciences landscape.

Discover the critical insights and recommendations that could reshape the future of healthcare in the UK.

#SyenzaNews #healthcarepolicy #innovation

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.